ANIK Anika Therapeutics, Inc. stock chart & analysis
Conviction 18HealthcareScan · Fri, Nov 6, 2026Anika Therapeutics, Inc. (ANIK) closed at $14.55 (-24.73%) on Nov 6, 2026. Its latest daily candle is a three outside down. Price is below its 50-day and below its 200-day moving average. RSI(14) 24, RS Rating 85, -36.5% from its 52-week high, +51.2% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Financials as of Wed, Sep 30, 2026 · quarterly.
ANIK technical analysis
Trend
ANIK's moving averages are mixed — no clean uptrend or downtrend. It closed 28.7% below the 50-day ($20.38) and 10.8% below the 200-day ($16.30). ADX(14) at 21 points to a moderate trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 24, in oversold territory. MACD crossed below its signal line 4 sessions ago. Its RS Rating of 85 puts its weighted 12-month performance ahead of about 85% of the US market.
Volume and volatility
It trades about $2.2M a day on average. ATR(14) is $1.30, 8.9% of price — its typical daily range. On-balance volume is trending up.
Key levels
The 52-week range is $9.01 to $22.88; price is 36.5% below the high and 61.3% above the low. The VWAP anchored at the 52-week high is $20.52, above price.
Performance
ANIK returned -30.6% (1 week), -24.4% (1 month), -29.7% (3 months), -1.6% (6 months), +47.6% (1 year), +51.2% (year to date).
About Anika Therapeutics, Inc.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Surgical & Medical Instruments & Apparatus · Listed 1993 · 235 employees
Insider activity
SEC Form 4 transactions in ANIK · open-market 3 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Fischetti Gary P Director · Common Stock · 2026-08-04 | Buy | 1K | $20K | 2026-08-04 | 2026-08-05 |
Fischetti Gary P Director · Common Stock · 2026-08-03 | Buy | 1K | $21K | 2026-08-03 | 2026-08-05 |
Griffin Stephen D. President and CEO · Common Stock · 2026-06-03 | Tax | 3.77K | $54K | 2026-06-03 | 2026-06-05 |
Griffin Stephen D. President and CEO · Common Stock · 2026-06-03 | Exercise | 12.84K | — | 2026-06-03 | 2026-06-05 |
Griffin Stephen D. President and CEO · Restricted Stock Unit · 2026-06-03 | Exercise | 12.84K | $0 | 2026-06-03 | 2026-06-05 |
HENNEMAN JOHN B III Director · Common Stock · 2026-05-01 | Buy | 5K | $73K | 2026-05-01 | 2026-05-04 |
SEC filings
EDGAR filings in ANIK · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.